Mirna Therapeutics Inc. (NASDAQ:MIRN) shares hit a new 52-week low on Monday . The stock traded as low as $2.95 and last traded at $2.95, with a volume of 181,962 shares traded. The stock had previously closed at $3.06.

MIRN has been the subject of several research analyst reports. Zacks Investment Research raised shares of Mirna Therapeutics from a “hold” rating to a “buy” rating and set a $5.00 target price for the company in a research note on Thursday, July 14th. Cantor Fitzgerald reaffirmed a “buy” rating and set a $14.00 target price on shares of Mirna Therapeutics in a research note on Friday, May 13th. Leerink Swann lowered shares of Mirna Therapeutics from an “outperform” rating to a “market perform” rating and lowered their target price for the stock from $10.00 to $4.00 in a research note on Monday, August 15th. Citigroup Inc. lowered shares of Mirna Therapeutics from a “buy” rating to a “neutral” rating and lowered their target price for the stock from $7.00 to $4.50 in a research note on Tuesday, August 16th. Finally, Oppenheimer Holdings Inc. increased their target price on shares of Mirna Therapeutics from $7.00 to $13.00 and gave the stock an “outperform” rating in a research note on Tuesday, August 16th. Three equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. The company has an average rating of “Hold” and a consensus target price of $8.10.

The firm’s market cap is $62.30 million. The stock has a 50 day moving average of $4.02 and a 200 day moving average of $4.33.

Mirna Therapeutics, Inc is a United States-based clinical-stage biopharmaceutical company. The Company is focused on developing a pipeline of microRNA (ribonucleic acid)-based oncology therapeutics. It is developing a cancer therapy, microRNA Replacement Therapy, focused on replacing naturally occurring microRNAs that are under expressed in cancer cells with microRNA mimics.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.